- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05364411
HYpofractionated, Dose-redistributed RAdiotherapy With Protons and Photons in HNSCC (HYDRA)
HYpofractionated, Dose-redistributed RAdiotherapy With Protons and Photons to Combat Radiation-induced Immunosuppression in Head and Neck Squamous Cell Carcinoma (HYDRA)
Radiotherapy for advanced-stage head and neck squamous cell carcinoma (HNSCC) results in an unfavorable 5-year overall survival of 40%, and there is a strong biological rationale for improving outcome by combinatorial treatment with immunotherapy. However, also immunosuppressive effects of radiotherapy have been reported and recently a randomized phase-III trial failed to show any survival benefit following the combination of a PD-L1 inhibitor with chemoradiotherapy. The hypothesis is that the combination of these individually effective treatments failed because of radiation-induced lymphodepletion and that the key therefore lies in reforming conventional radiotherapy, which typically consists of large lymphotoxic radiation fields of 35 fractions. By integrating modern radiobiology and individually established innovative radiotherapy concepts, the patient's immune system could be maximally retained. This will be achieved by 1) increasing the radiation dose per fraction so that the total number of fractions can be reduced (HYpofractionation), 2) by redistributing the radiation dose towards a higher peak dose within the tumor center and a lowered elective-field dose (Dose-redistribution) and 3) by using RAdiotherapy with protons instead of photons (HYDRA).
The objectives of this study are to determine the safety of HYDRA with protons and photons by conducting two parallel phase-I trials. HYDRA's efficacy will be compared to standard of care (SOC). The immune effects of HYDRA-protons will be evaluated by longitudinal immune profiling and compared to HYDRA-photons and SOC (with protons and photons). There will be a specific focus on actionable immune targets and their temporal patterns that can be tested in future hypofractionated-immunotherapy combination trials. This trial therefore is an important step towards future personalized immuno-radiotherapy combinations with the ultimate goal to improve survival for patients with HNSCC.
Study Overview
Status
Conditions
Detailed Description
The HYDRA dose prescriptions are, in 20 fractions (instead of the conventional 35 fractions):
- Inhomogeneous focal boost on the macroscopic gross tumor volume (GTVprimary tumor and GTVnodes) on FDG-PET: mean dose 59Gy, max dose 63Gy.
- The mean dose of 59Gy corresponds to an equal late normal tissue toxicity probability after conventionally fractionated radiotherapy of 70Gy in 35 fractions, considering an α/β=3 for normal tissue.
- Simultaneous integrated boost (SIB) on the clinical target volume (CTV-P1 = GTV+5mm): 55Gy
- Elective field / CTV-P2 (GTV+10mm): 40Gy
Patients who receive the HYDRA intervention treatment, as well as patients who receive standard of care may require the addition of a concurrent radiosensitizer based on clinicopathological features according to standard of care. Currently, the only two registered radiosensitizers are platinum-based chemotherapy (cisplatin/carboplatin) and cetuximab. These radiosensitizers should be administered according to standard care treatment protocols.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Joris BW Elbers, MD, PhD
- Phone Number: 0031207041249
- Email: j.elbers@erasmusmc.nl
Study Locations
-
-
Zuid Holland
-
Rotterdam, Zuid Holland, Netherlands, 3015 GL
- Recruiting
- Erasmus MC
-
Contact:
- Jos Elbers
- Phone Number: 0031107041249
- Email: j.elbers@erasmusmc.nl
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
In order to be eligible to participate in this study, a subject must meet all of the following criteria:
- ≥ 18 years old at time of signing informed consent.
- WHO 0-2
- Squamous cell carcinoma of the oropharynx, hypopharynx and larynx* proven by cytology / histology
- Patients amenable for curative intent proton therapy (by model-based selection criteria, according to the Dutch standard of care) or photon therapy.
- Radiotherapy with or without concurrent radiosensitizer.
- Ability to understand the requirements of the study and to give written informed consent, as determined by the treating physician.
Written informed consent obtained.
- Note: The HYDRA dose prescriptions should be applicable for all HNSCC patients and should therefore ideally be tested within the full range of treatment indications, e.g. multiple tumor subsites and both chemoradiotherapy and radiotherapy alone. There are several reports about acceptable acute toxicity following hypofractionated chemoradiotherapy in advanced stage HNSCC. However, concerns about late toxicity remain, especially for laryngeal carcinoma. Patients with laryngeal carcinoma are therefore initially excluded, until these patients are also considered eligible for treatment with HYDRA. The statistical considerations and interim safety analyses for this purpose and the decision-making / consultation are further described elsewhere.
Exclusion criteria
Patients who do not meet the inclusion criteria as specified in paragraph 4.2, and/or who meet the following additional criteria:
- Previously treated by irradiation on the same target volume
- Chronic inflammatory disease or immune disorders which, according to the principal investigator, may disturb the translational immune-read out.
- Patients currently under treatment for other malignant disease (unless in situ carcinoma or basal cell carcinoma of the skin), or treated for other malignant disease within the last 2 years.
- Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule in the participating hospitals.
- Any other serious medical condition that could interfere with follow-up.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: HYDRA-protons
group 1, n=25, run at HollandPTC
|
20 daily fractions, 5 times per week
|
Active Comparator: Conventional fractionated proton therapy
group 2, n=25, run at HollandPTC
|
35 daily fractions, 5 times per week
|
Experimental: HYDRA-photons
group 3, n=25 run at Erasmus MC
|
20 daily fractions, 5 times per week
|
Active Comparator: Conventional fractionated photon therapy
group 4, n=25 run at Erasmus MC
|
35 daily fractions, 5 times per week
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety of HYDRA-protons and HYDRA-photons in terms of radiation-induced grade 3-4 late toxicity, physician-reported by CTCAE v5.0, monitored until 1 year after the last patient has completed HYDRA.
Time Frame: month 1-36
|
HYDRA is randomized with standard of care for translational research purposes; a direct comparison of toxicity will statistically not be conclusive and is outside the scope of this study.
|
month 1-36
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective response after HYDRA defined by radiological response on CT-scans or MRI in comparison to standard of care
Time Frame: month 1-27
|
Objective response rate 3 months after HYDRA (group 1 and 3), defined by radiological response on CT-scans or MRI using RECIST version 1.1 and/or histopathological confirmation of residual disease, in comparison to standard of care (group 2 and 4, respectively), 3 months after end of treatment
|
month 1-27
|
Efficacy of HYDRA in terms of in-field and nodal elective field tumor control at 1 year
Time Frame: month 24-36
|
Efficacy of HYDRA (group 1 and 3) in terms of in-field and nodal elective field tumor control, 1 year after the last patient is included, in comparison to group 2 and 4, respectively.
|
month 24-36
|
Immune profile (changes) between all 4 treatment groups
Time Frame: month 1-27
|
Numbers and phenotype of peripheral immune cell populations in blood at baseline, related to patient- and tumor characteristics, and differences between temporal changes of these immune markers during/after treatment at 6 timepoints in group 1-4.
|
month 1-27
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Joris BW Elbers, MD, PhD, Erasmus MC, Rotterdam / HollandPTC, Delft - The Netherlands
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HYDRA
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Head and Neck Squamous Cell Carcinoma
-
Washington University School of MedicineMerck Sharp & Dohme LLCActive, not recruitingHead and Neck Cancer | Squamous Cell Carcinoma of the Head and Neck | Cancer of Head and Neck | Carcinoma, Squamous Cell of Head and Neck | Neoplasms, Head and Neck | Squamous Cell Carcinoma, Head and NeckUnited States
-
Chase Heaton, MDIncyte Corporation; OncoSec Medical IncorporatedTerminatedRecurrent Head and Neck Squamous Cell Carcinoma | Metastatic Head and Neck Squamous Cell Carcinoma | Unresectable Head and Neck Squamous Cell CarcinomaUnited States
-
Xiang LuRecruitingHead and Neck Squamous Cell Carcinomas | Resectable Head and Neck Squamous-cell CarcinomaChina
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)RecruitingRecurrent Head and Neck Squamous Cell Carcinoma | Advanced Head and Neck Squamous Cell Carcinoma | Metastatic Head-and-neck Squamous-cell Carcinoma | Locally Advanced Head and Neck Squamous Cell Carcinoma | Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck | Stage IV Cutaneous...United States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)RecruitingHead and Neck Squamous Cell Carcinoma | Recurrent Head and Neck Squamous Cell Carcinoma | Metastatic Head-and-neck Squamous-cell CarcinomaUnited States
-
Washington University School of MedicineActive, not recruitingSquamous Cell Carcinoma of the Head and Neck | Squamous Cell Carcinoma, Head and NeckUnited States
-
Yonsei UniversityCompletedHead Neck Cancer Squamous Cell Recurrent | Head Neck Cancer Squamous Cell MetastaticKorea, Republic of
-
National Taiwan University HospitalUnknownHead-and-Neck Squamous Cell CarcinomaTaiwan
-
Medical College of WisconsinRecruitingResectable Head and Neck Squamous Cell CarcinomaUnited States
-
Eben RosenthalNational Cancer Institute (NCI)CompletedHead and Neck Cancer | Head and Neck Squamous Cell Carcinoma | Squamous Cell Carcinoma of the Head and Neck (SCCHN)United States
Clinical Trials on HYpofractionated, Dose-redistributed RAdiotherapy (HYDRA)
-
M.D. Anderson Cancer CenterCancer Prevention Research Institute of TexasRecruitingSquamous Cell Carcinoma of the Larynx | Malignant Neoplasms of Respiratory and Intrathoracic OrgansUnited States
-
National University Hospital, SingaporeTan Tock Seng HospitalUnknownStage III Non-Small Cell Lung CancerSingapore
-
Centre Francois BaclesseAssociation de Neuro-Oncologues d'Expression FrancaiseActive, not recruitingBrain Metastasis | OligoprogressionFrance
-
Maria Sklodowska-Curie National Research Institute...RecruitingRecurrent Soft Tissue Sarcoma | Recurrent Sarcoma | Radiation Induced Neoplasms | Radiation-Induced CancerPoland
-
Hospital da BaleiaUnknownBreast Cancer | Radiation Toxicity
-
University of UtahNational Cancer Institute (NCI)RecruitingCervical Carcinoma | Endometrial CarcinomaUnited States
-
University Hospital HeidelbergRecruitingProstate CancerGermany
-
University of UtahActive, not recruitingStage 0 Breast Cancer | Stage I Breast Cancer | Stage II Breast Cancer | Invasive Breast Carcinoma | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Ductal Breast Carcinoma In SituUnited States
-
Cancer Institute and Hospital, Chinese Academy...RecruitingBreast CarcinomaChina
-
Medical University of GrazTerminatedProstate Cancer | Radiotherapy Side EffectAustria